Literature DB >> 16039715

Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia.

Yang Yang1, Seisho Takeuchi, Wolf K Hofmann, Takayuki Ikezoe, Jacques J M van Dongen, Tomasz Szczepański, Claus R Bartram, Norihide Yoshino, Hirokuni Taguchi, H Phillip Koeffler.   

Abstract

Methylation profile was analyzed in 10 childhood acute lymphoblastic leukemia (ALL) and nine adult ALL cases. Four genes (p15, p16, RARbeta, FHIT) had methylation in both diseases, four genes (p14, Rb, MLH1, DAPK) showed no methylation in both diseases, and the two genes (APC, RIZ) demonstrated methylation only in adult ALL. Methylation of the RARbeta was more frequent in adult ALL than that in childhood ALL (p=0.01). The number of patients with methylation of multiple genes was higher in adult ALL than that in childhood ALL (p=0.006). Moreover, overall frequency of methylation was higher in adult ALL than that in childhood ALL (p=0.01).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039715     DOI: 10.1016/j.leukres.2005.06.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.

Authors:  Vivien Schäfer; Jana Ernst; Jenny Rinke; Nils Winkelmann; James F Beck; Andreas Hochhaus; Bernd Gruhn; Thomas Ernst
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-11       Impact factor: 4.553

Review 3.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

4.  Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.

Authors:  De-Tao Yin; Lin Wang; Jianrui Sun; Fengyan Yin; Qingtao Yan; Rulong Shen; Gang He; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-05-25

5.  Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia.

Authors:  Seisho Takeuchi; Masahide Matsushita; Martin Zimmermann; Takayuki Ikezoe; Naoki Komatsu; Taku Seriu; Martin Schrappe; Claus R Bartram; H Phillip Koeffler
Journal:  Leuk Res       Date:  2011-05-17       Impact factor: 3.156

6.  Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC.

Authors:  Mingchuan Zhao; Yishi Zhang; Jiayu Li; Xuefei Li; Ningning Cheng; Qi Wang; Weijing Cai; Chao Zhao; Yayi He; Jianhua Chang; Caicun Zhou
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

7.  Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia.

Authors:  Maria E Figueroa; Shann-Ching Chen; Anna K Andersson; Letha A Phillips; Yushan Li; Jason Sotzen; Mondira Kundu; James R Downing; Ari Melnick; Charles G Mullighan
Journal:  J Clin Invest       Date:  2013-06-10       Impact factor: 14.808

8.  Evaluation of LKB1 and Serine-Glycine Metabolism Pathway Genes (SHMT1 and GLDC) Expression in AML.

Authors:  Fateme Mezginejad; Mohammad Hossein Mohammadi; Parinaz Khadem; Mehdi Allahbakhshian Farsani
Journal:  Indian J Hematol Blood Transfus       Date:  2020-08-14       Impact factor: 0.900

9.  Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia.

Authors:  Robert J Weeks; Ursula R Kees; Sarah Song; Ian M Morison
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

Review 10.  DNA methylation as a potential mediator of environmental risks in the development of childhood acute lymphoblastic leukemia.

Authors:  Jessica A Timms; Caroline L Relton; Judith Rankin; Gordon Strathdee; Jill A McKay
Journal:  Epigenomics       Date:  2016-04-01       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.